skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Ranibizumab (Code C67562)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ranibizumab

Definition: A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.

Display Name: Ranibizumab

Label: Ranibizumab

NCI Thesaurus Code: C67562 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1566537  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain

External Source Codes: 
CAS Registry Number 347396-82-1 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 544572
PDQ Open Trial Search ID 544572 (check for NCI PDQ open clinical trial info)
UMLS CUI C1566537

Other Properties:
     Name Value (qualifiers indented underneath)
code C67562
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Ranibizumab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: Yes  


Mainbox Bottom